Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Currently Dr Reddy’s, Cipla and Zydus derive significant portion of their earnings from generic Revlimid; Realisations on generic Revlimid can fall in second half of ...

Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...

Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...

B&K Securities is bullish on CarTrade Tech Ltd., and holds that the company is a classic non-linear business with growth ...

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...